Combining evidence-based psychosocial and pharmacological treatments significantly benefits the global quality of life of first episode psychosis patients when compared with standard community care. But the benefits of comprehensive, integrated management seen in the RAISE study diminish as duration of untreated psychosis increases. We can intervene to aid functional and clinical recovery after first episode psychosis, but it must be with the right treatment given at the right time.
Related content
In this video Professor Christoph Correll discusses the challenges with available schizophrenia treatments & what clinicians should keep in mind when considering the emerging treatment options for schizophrenia.
The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.
LDT=Laterodorsal tegmental nucleus; NAc = Nucleus Accumbens; SN = Substantia Nigra; VTA = Ventral Tegmental Area.